Belderbos Robert A, Vroman Heleen, Aerts Joachim G J V
Department of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, Netherlands.
Erasmus MC Cancer Institute, Erasmus MC Rotterdam, Rotterdam, Netherlands.
Front Oncol. 2020 Jun 3;10:777. doi: 10.3389/fonc.2020.00777. eCollection 2020.
Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. Unfortunately, clinical studies that investigate the effectivity of checkpoint inhibitor (CI) treatment failed to improve clinical outcome over current applied therapies. In general, MPM is characterized as an immunological cold tumor with low T-cell infiltration, which could explain the disappointing results of clinical trials investigating CI treatment in MPM. Currently, many other therapeutic approaches, such as cellular therapies and cancer vaccines are investigated that could induce a tumor-specific immune response and increase of the number of tumor-infiltrating lymphocytes. In this review we will discuss these novel treatment approaches for MPM.
恶性胸膜间皮瘤（MPM）是一种治疗棘手的肿瘤，总体生存率（OS）较低。目前获批的治疗方法是一线化疗，其仅适度提高了OS，这表明MPM迫切需要其他治疗选择。不幸的是，研究检查点抑制剂（CI）治疗有效性的临床研究未能比当前应用的疗法改善临床结局。一般而言，MPM的特征是T细胞浸润低的免疫冷肿瘤，这可以解释在MPM中研究CI治疗的临床试验结果令人失望的原因。目前，正在研究许多其他治疗方法，如细胞疗法和癌症疫苗，它们可以诱导肿瘤特异性免疫反应并增加肿瘤浸润淋巴细胞的数量。在本综述中，我们将讨论MPM的这些新型治疗方法。
